Cover Image
市場調查報告書

靜脈性腳潰瘍(小腿潰瘍) - 開發平台分析

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255952
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
靜脈性腳潰瘍(小腿潰瘍) - 開發平台分析 Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 69 Pages
簡介

由於腿部靜脈高壓,造成皮膚持續受損,就會引發靜脈性腳潰瘍。該部位會受損而形成潰瘍。症狀有按壓時會暫時留下指痕(壓痕水腫),腳踝有充滿體液的腫起,變色的潰瘍四周皮膚變硬、腳感覺變硬,形成倒香檳酒瓶的狀態、白皮膚上小小光滑的部位有小小的紅色斑點(白色萎縮)等。

本報告提供靜脈性腳潰瘍(小腿潰瘍)的治療藥開發平台現況及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等資料。

簡介

  • 調查範圍

靜脈性腳潰瘍(小腿潰瘍) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Adocia
  • CardioVascular BioTherapeutics, Inc.
  • CoDa Therapeutics, Inc
  • CytoTools AG
  • FirstString Research, Inc.
  • Intralytix, Inc.
  • MacroCure Ltd
  • Pergamum AB
  • RegeneRx Biopharmaceuticals, Inc
  • Smith & Nephew Plc
  • Stratatech Corporation

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Cathelicidin
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers
  • CL-05
  • CODA-001
  • CureXcell
  • CVBT-141B
  • Granexin
  • HP-802247
  • LL-37
  • Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases
  • RGN-137
  • WPP-201
  • Venous Leg Ulcers (Crural ulcer)

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8960IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 7, 1, 5 and 1 respectively.

Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Venous Leg Ulcers (Crural ulcer) - Overview
  • Venous Leg Ulcers (Crural ulcer) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development
  • Adocia
  • CardioVascular BioTherapeutics Inc
  • CytoTools AG
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • Mallinckrodt Plc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • Promore Pharma
  • RegeneRx Biopharmaceuticals Inc
  • RMB-Research GmbH
  • Venous Leg Ulcers (Crural ulcer) - Drug Profiles
  • AUP-16 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biochaperone PDGF-BB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CL-05 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CODA-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CureXcell - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CVBT-141B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EscharEx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Granexin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LL-37 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NLP-328 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RGN-137 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-42909 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sodium hypochlorite - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Statmicoll - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VF-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Venous Leg Ulcers (Crural ulcer) - Dormant Projects
  • Venous Leg Ulcers (Crural ulcer) - Discontinued Products
  • Venous Leg Ulcers (Crural ulcer) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update
  • Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)
  • Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US
  • Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board
  • May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial
  • Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
  • Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers
  • Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
  • Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results
  • Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications
  • May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication
  • Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers
  • Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results
  • Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Factor Therapeutics Ltd, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research Inc, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Mallinckrodt Plc, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by Promore Pharma, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Pipeline by RMB-Research GmbH, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2017
  • Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top